medigraphic.com

2014, Number 5

<< Back Next >>

Cir Cir 2014; 82 (5)

Genetic variants in miRNAs and its association with breast cancer

Méndez-Gómez S, Ruiz Esparza-Garrido R, Velázquez-Flores M, Dolores-Vergara M, Salamanca-Gómez F, Arenas-Aranda DJ

Language: Spanish
References: 20
Page: 489-495
PDF size: 510.86 Kb.


ABSTRACT

Background: In Mexico, breast cancer represents the first cause of cancer death in females. At the molecular level, non-coding RNAs and especially microRNAs have played an important role in the origin and development of this neoplasm. In the Anglo-Saxon population, diverse genetic variants in microRNA genes and in their targets are associated with the development of this disease. In the Mexican population it is not known if these or other variants exist. Identification of these or new variants in our population is fundamental in order to have a better understanding of cancer development and to help establish a better diagnostic strategy.
Methods: DNA was isolated from mammary tumors, adjacent tissue and peripheral blood of Mexican females with or without cancer. From DNA, five microRNA genes and three of their targets were amplified and sequenced. Genetic variants associated with breast cancer in an Anglo- Saxon population have been previously identified in these sequences.
Results: In the samples studied we identified seven single nucleotide polymorphisms (SNPs). Two had not been previously described and were identified only in women with cancer.
Conclusion: The new variants may be genetic predisposition factors for the development of breast cancer in our population. Further experiments are needed to determine the involvement of these variants in the development, establishment and progression of breast cancer.


REFERENCES

  1. Vogelstein B, Kinzler KW. The Genetic basis of human cancer. 2nd ed. New York: McGraw-Hill; 2002;821.

  2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin M. Globocan 2008 v2.0: Cancer Incidente and Mortality Worldwide. IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Globocan (breast, Word) (consultado 2013 Sep 11). Disponible en http:// globocan.iarc.fr

  3. Cardenas S, Erazo A, Maafs E, Poitevin A. Cuarta revisión del Consenso Nacional sobre el diagnóstico y tratamiento del cáncer mamario. Colima, México, 2011. (consultado 2013 Sep 12). Disponible en http://consensocancermamario. com

  4. Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connoly J, et al. Defining breast cancer prognosis base on molecular phenotypes: results from a large cohorte study. Breast Cancer Res Treat 2011;126(1):185-192.

  5. Mattick JS. RNA regulation: a new genetics? Nat Rev Genet 2004;5:316-323.

  6. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6(4):259-269.

  7. Le Quesne J, Caldas C. Micro-RNAs and breast cancer. Mol Oncol 2010;4(3):230-241.

  8. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010;10(6):389-402.

  9. Sambrook F, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. New York: CHL Press; 2001. p. 2344.

  10. Faculty of life Sciences. University of Manchester. miRBase: the microRNA database. United Kingdom. 2013. Nucl Acids Res. 2013;41(D1):D48-D55. (consultado 2013 Sep 12). Disponible en http://www.mirbase.org

  11. Ensembl 2013. United Kingdom. Regents of the EMBL-EBI and Wellcome Trust Sanger Institute 2013. (consultado 2013 Sep 13). Disponible en http://www.ensembl.org.

  12. Untergrasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3-new capabilities and interfaces. Nucleic Acids Res 2012;40(15):e115.

  13. National Center for Biotechnology Information (NCBI). United States 2013. (consultado 2013 Sep 13). Disponible en www.ncbi.nlm.nih.gov.

  14. mFold 3.5. New York: Regents of the RNA Institute, Collage of Arts and Sciences, State University of New York at Albany 2013. (consultado 2013 Sep 13). Disponible en http:// mfold.rna.albany.edu/?q=mfold.

  15. Database of single nucleotide polymorphisms (SNPs) (dbSNP-NCBI). United States 2013. (consultado 2013 Sep 13). Disponible en www.ncbi.nlm.nih.gov/snp.

  16. Tchatchou S, Jung A, Hemminhi K, Sutter C, Wappenschmidt B, Bugert P, et al. A variante affecting a puntative miRNA target site in estrogeno receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis 2009;30(1):59-64.

  17. Yang R, Schlehe B, Hemminhi K, Sutter C, Bugert P, Wappenschmidt B, et al. A genetic variante in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat 2010;121(3):693-702.

  18. Slaby O, Bienertova-Vasku J, Svoboda M, Vyzuela R. Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J Cell Mol Med 2012;16(1):8- 21.

  19. Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A funcional polymorphism in the miR-146α gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008;29(10):1963-1966.

  20. Song F, Zheng H, Liu B, Wei S, Dai H, Zhang L, et al. An miR-502-Binding Site Single-Nucleotide Polymorphism in the 3’-Untranslated Region of the SET8 Gene Is Associated with Early Age of Breast Cancer Onset. Clin Cancer Res 2009;15(19):6292-6300.




2020     |     www.medigraphic.com